CAMP4 Therapeutics Advances SYNGAP1 Rare Disease Treatment into Human Trials in Australia
CAMP4 Therapeutics has received regulatory approval in Australia to begin human trials for its antisense oligonucleotide therapy targeting SYNGAP1-related disorders, a significant step for patients with this rare genetic condition that currently lacks approved treatments.